KR102785140B1 - 신규 항-cd3엡실론 항체 - Google Patents

신규 항-cd3엡실론 항체 Download PDF

Info

Publication number
KR102785140B1
KR102785140B1 KR1020207011016A KR20207011016A KR102785140B1 KR 102785140 B1 KR102785140 B1 KR 102785140B1 KR 1020207011016 A KR1020207011016 A KR 1020207011016A KR 20207011016 A KR20207011016 A KR 20207011016A KR 102785140 B1 KR102785140 B1 KR 102785140B1
Authority
KR
South Korea
Prior art keywords
seq
antibody
antigen
ser
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207011016A
Other languages
English (en)
Korean (ko)
Other versions
KR20200055052A (ko
Inventor
징 리
친 메이
Original Assignee
우시 바이올로직스 아일랜드 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우시 바이올로직스 아일랜드 리미티드 filed Critical 우시 바이올로직스 아일랜드 리미티드
Priority to KR1020257008876A priority Critical patent/KR20250046337A/ko
Publication of KR20200055052A publication Critical patent/KR20200055052A/ko
Application granted granted Critical
Publication of KR102785140B1 publication Critical patent/KR102785140B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207011016A 2017-09-21 2018-09-20 신규 항-cd3엡실론 항체 Active KR102785140B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257008876A KR20250046337A (ko) 2017-09-21 2018-09-20 신규 항-cd3엡실론 항체

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/102622 2017-09-21
CN2017102622 2017-09-21
PCT/CN2018/106618 WO2019057099A1 (en) 2017-09-21 2018-09-20 NOVEL ANTI-CD3EPSILON ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257008876A Division KR20250046337A (ko) 2017-09-21 2018-09-20 신규 항-cd3엡실론 항체

Publications (2)

Publication Number Publication Date
KR20200055052A KR20200055052A (ko) 2020-05-20
KR102785140B1 true KR102785140B1 (ko) 2025-03-25

Family

ID=65811028

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207011016A Active KR102785140B1 (ko) 2017-09-21 2018-09-20 신규 항-cd3엡실론 항체
KR1020257008876A Pending KR20250046337A (ko) 2017-09-21 2018-09-20 신규 항-cd3엡실론 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257008876A Pending KR20250046337A (ko) 2017-09-21 2018-09-20 신규 항-cd3엡실론 항체

Country Status (18)

Country Link
US (2) US11440962B2 (OSRAM)
EP (1) EP3684806A4 (OSRAM)
JP (2) JP7305624B2 (OSRAM)
KR (2) KR102785140B1 (OSRAM)
CN (2) CN111108119B (OSRAM)
AU (2) AU2018336519B2 (OSRAM)
BR (1) BR112020004992A2 (OSRAM)
CA (1) CA3074130A1 (OSRAM)
EA (1) EA202090800A1 (OSRAM)
IL (1) IL273393A (OSRAM)
MX (1) MX2020003087A (OSRAM)
MY (1) MY199530A (OSRAM)
PH (1) PH12020550078A1 (OSRAM)
SA (2) SA523440043B1 (OSRAM)
SG (1) SG11202001358RA (OSRAM)
TW (2) TWI820041B (OSRAM)
WO (1) WO2019057099A1 (OSRAM)
ZA (1) ZA202001314B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL273424B2 (en) 2017-09-22 2024-09-01 Wuxi Biologics Ireland Ltd Novel bispecific cd3/cd19 polypeptide complexes
IL273217B2 (en) 2017-09-22 2025-04-01 Wuxi Biologics Ireland Ltd Novel bispecific polypeptide complexes
EP3973000A4 (en) * 2019-06-07 2023-09-06 Adimab, LLC HIGH AFFINITY ANTI-CD3 ANTIBODIES AND METHOD FOR THE PRODUCTION AND USE THEREOF
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
JP7765397B2 (ja) 2020-03-12 2025-11-06 イミューン－オーエヌシー セラピューティクス，インコーポレーテッド 新規抗ｌｉｌｒｂ４抗体および派生産物
JP2023528350A (ja) 2020-05-27 2023-07-04 ヤンセン バイオテツク，インコーポレーテツド Ｃｄ３抗原結合ドメインを含むタンパク質及びその使用
WO2022022464A1 (zh) * 2020-07-27 2022-02-03 正大天晴药业集团股份有限公司 新型双特异性抗cd3/cd20多肽复合物配制剂
US11795224B2 (en) * 2021-03-24 2023-10-24 China Medical University Hospital Anti-T-cell nanobody and nucleic acid encoding sequence thereof, and uses of the same
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
CN115558023A (zh) * 2021-07-02 2023-01-03 安源医药科技（上海）有限公司 抗cd3抗体及其用途
CN118922442A (zh) * 2022-03-14 2024-11-08 成都盛世君联生物技术有限公司 一种抗cd3抗体及其制备方法和用途
CN115286715B (zh) * 2022-05-18 2023-05-23 上海百英生物科技股份有限公司 一种抗cd3的纳米抗体或其抗原结合部分及其制备方法
AU2023367039A1 (en) * 2022-10-25 2025-05-15 Ablexis, Llc Anti-cd3 antibodies
EP4623007A1 (en) 2022-11-24 2025-10-01 WuXi Biologics Ireland Limited Psma antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
CN1169953C (zh) * 1999-11-30 2004-10-06 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd3单克隆抗体重链和轻链可变区基因及其应用
UA94211C2 (ru) * 2004-06-03 2011-04-26 Новиммюн С.А. Выделенное полностью человеческое моноклональное cd3 антитело
DK1940881T3 (en) * 2005-10-11 2017-02-20 Amgen Res Munich Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
CA2682626A1 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
FI2155783T4 (fi) * 2007-04-03 2022-12-15 Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
WO2010037836A2 (en) 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
WO2011109588A1 (en) 2010-03-03 2011-09-09 Health Research Inc. Novel cd3 epsilon immunogens and antibodies
CN104098698B (zh) * 2013-04-08 2019-04-05 中国人民解放军第二军医大学 一种抗cd3抗体及其制法和应用
SG11201509361TA (en) * 2013-05-28 2015-12-30 Numab Ag Novel antibodies
CN112390883A (zh) 2013-12-17 2021-02-23 基因泰克公司 抗cd3抗体及使用方法
AU2015266077A1 (en) 2014-05-28 2016-09-29 F. Hoffmann-La Roche Ag Antibodies binding to human and cynomolgus CD3 epsilon
AU2015329965A1 (en) * 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1
TN2018000324A1 (en) * 2015-01-23 2020-01-16 Sanofi Sa ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123

Also Published As

Publication number Publication date
CN111108119B (zh) 2022-11-15
TWI820041B (zh) 2023-11-01
CN111108119A (zh) 2020-05-05
KR20250046337A (ko) 2025-04-02
TW202428617A (zh) 2024-07-16
MY199530A (en) 2023-11-03
NZ762170A (en) 2023-10-27
MX2020003087A (es) 2020-08-17
TWI879275B (zh) 2025-04-01
US20200299384A1 (en) 2020-09-24
BR112020004992A2 (pt) 2020-10-06
US11440962B2 (en) 2022-09-13
EA202090800A1 (ru) 2020-08-11
JP7737193B2 (ja) 2025-09-10
TW201922787A (zh) 2019-06-16
SA523440043B1 (ar) 2024-02-08
ZA202001314B (en) 2021-08-25
WO2019057099A1 (en) 2019-03-28
CN115991777A (zh) 2023-04-21
KR20200055052A (ko) 2020-05-20
US20230192850A1 (en) 2023-06-22
SG11202001358RA (en) 2020-03-30
AU2025201457A1 (en) 2025-03-20
PH12020550078A1 (en) 2022-07-18
AU2018336519A1 (en) 2020-03-05
JP7305624B2 (ja) 2023-07-10
JP2020534830A (ja) 2020-12-03
EP3684806A4 (en) 2021-09-22
EP3684806A1 (en) 2020-07-29
SA520411577B1 (ar) 2024-02-08
US12485298B2 (en) 2025-12-02
JP2023126851A (ja) 2023-09-12
AU2018336519B2 (en) 2024-12-19
CA3074130A1 (en) 2019-03-28
IL273393A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
KR102785140B1 (ko) 신규 항-cd3엡실론 항체
CN112218892B (zh) 新型抗ctla-4抗体多肽
US20240052052A1 (en) Novel anti-cd24 antibodies
JP7438180B2 (ja) 新規抗ｌａｇ－３抗体ポリペプチド
JP2025509336A (ja) 新規抗ｃｄ３抗体およびその使用
KR20240025513A (ko) 신규 항-cd276 항체 및 이의 용도
US12486325B2 (en) Anti-CD3epsilon antibodies
US20250368734A1 (en) Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
EA042856B1 (ru) Новые анти-cd3-эпсилон антитела
TW202413417A (zh) 新穎抗ｃｄ３抗體及其用途
KR20250108115A (ko) 신규 다중특이적 항체 및 이의 용도
NZ762170B2 (en) Novel anti-cd3epsilon antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200416

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210917

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240422

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241218

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250318

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250319

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PA0102 Application to register extension of term of patent right following delayed registration